Introduction
Vasoactive peptide systems shape vascular tone, organ perfusion, extracellular matrix turnover, and stress-adaptive signaling through G-protein–coupled receptors (GPCRs). Within this landscape, the relaxin family peptide receptor 1 (RXFP1) has attracted sustained interest because its endogenous ligand, human relaxin-2, coordinates cAMP/PKA-, ERK-, and nitric-oxide–linked pathways that influence endothelial function, myofibroblast biology, and cellular stress responses in controlled experimental settings. However, native relaxin-2 is a two-chain, disulfide-rich peptide with manufacturing and stability constraints, motivating the design of minimal, single-chain surrogates that preserve key receptor interactions while biasing downstream signaling toward desired nodes.
B7-33 peptide is a synthetically engineered, single-chain peptidomimetic modeled on the B-chain of relaxin-2 that engages RXFP1 but appears to favor specific intracellular cascades relative to the parent hormone in preclinical studies. Initial reports describe rapid endothelial effects, modulation of bradykinin-sensitive relaxation, and attenuation of stress markers in cardiomyocytes in vitro, alongside improvements in functional readouts in rodent models. Below, we synthesize mechanistic themes that have emerged from these investigations, emphasizing receptor pharmacology, signal bias, and tissue-level phenotypes observed in experimental systems.
Ligand Engineering and Receptor Engagement
B7-33 was designed to simplify the complex A/B-chain architecture of relaxin-2 into a single-chain sequence that retains the RXFP1-interacting pharmacophore. This downsizing removes disulfide bonds and reduces synthetic complexity, facilitating production and enabling systematic structure–activity exploration. Binding and functional assays indicate that B7-33 behaves as a functionally selective RXFP1 agonist, i.e., it activates the receptor yet accentuates particular downstream pathways rather than recapitulating the full breadth of relaxin-2 signaling. Such bias likely reflects altered orthosteric contacts and receptor conformations that differentially recruit G proteins and scaffolding proteins (e.g., β-arrestins), thereby reshaping the balance between cAMP/PKA and MAPK modules. In practice, this can translate to robust ERK1/2 phosphorylation with comparatively modest cAMP accumulation, a profile that may be advantageous when the research goal is to probe cytoprotective or anti-fibrotic programs without strong chronotropic or broad cAMP-driven outputs in vitro.
Signal Transduction Bias: ERK Emphasis with Context-Dependent cAMP
RXFP1 couples to multiple intracellular partners, and ligand-dependent bias can reorganize the downstream signaling “fingerprint.” In cellular systems, B7-33 has been observed to preferentially enhance ERK1/2 activity, consistent with survival- and remodeling-linked transcriptional responses, while still permitting context-dependent crosstalk with cAMP/PKA. Such a profile aligns with reduced endoplasmic reticulum (ER) stress markers (e.g., GRP78/BiP) in cardiomyocyte models exposed to simulated ischemia–reoxygenation or tunicamycin challenge, suggesting that biased RXFP1 activation may dampen unfolded protein response (UPR) burden. Mechanistically, ERK-centric signaling could converge on downstream effectors that regulate protein folding capacity, oxidative stress adaptation, and mitochondrial function—domains commonly implicated in cytoprotection paradigms.
Endothelial Modulation and Microvascular Physiology
In intact vessel preparations, acute B7-33 exposure enhances endothelium-dependent relaxation in mesenteric arteries by amplifying endothelium-derived hyperpolarization (EDH) pathways, while sparing large-artery responses in certain settings. This selective microvascular effect aligns with RXFP1 expression patterns and the propensity of smaller resistance vessels to rely on EDH rather than solely nitric oxide for vasorelaxation. Additionally, B7-33 and relaxin-2 show comparable capacity to preserve endothelial function ex vivo when arteries are challenged with trophoblast-conditioned media that induces preeclampsia-like endothelial dysfunction. Together, these observations position B7-33 as a useful probe for dissecting RXFP1-dependent endothelial signaling, bradykinin pathway facilitation, and microvascular coupling in preclinical models.
Cardiomyocyte Stress Responses and Tissue Remodeling
In mouse models of transient coronary occlusion–reperfusion, B7-33 administration in experimental settings has been associated with smaller histologic injury zones and preserved contractile indices over early time frames. Complementary in vitro experiments reveal improved survival of adult cardiomyocytes and suppression of ER-stress markers under simulated ischemic conditions, an effect that appears ERK1/2-dependent. These data suggest a working model in which RXFP1 activation by B7-33 reduces acute stress signaling, limits maladaptive remodeling cascades, and maintains myocyte performance. The mechanistic links likely involve modulation of UPR signaling, anti-apoptotic gene programs, and matrix-cell crosstalk—avenues well suited to further dissection using pathway inhibitors and transcriptomic profiling.
Placental Cell Models and Angiogenic Balance
Cytotrophoblast (CTB) cultures offer a platform to interrogate angiogenic factor dynamics relevant to placental vascular biology. Under hyperglycemic challenge, CTBs exhibit an anti-angiogenic shift characterized by elevated soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), with reduced VEGF/PlGF secretion. Co-exposure to B7-33 in these systems attenuates the anti-angiogenic profile and increases VEGF output, while activating mTOR and phosphorylated Akt (with total Akt unchanged), indicating engagement of pro-survival and pro-growth signaling nodes downstream of RXFP1. Although these are cell-based observations, they underscore the breadth of RXFP1 biology and the utility of B7-33 as a selective tool to probe trophoblast survival pathways and endothelial–trophoblast signaling axes under metabolic stress.
Production Practicalities and Translational Considerations (Preclinical)
Relative to two-chain, disulfide-bonded relaxin-2 (e.g., serelaxin), the single-chain design of B7-33 simplifies synthesis and may improve manufacturability for laboratory use, including peptide stability, cost, and scalability. From a pharmacology standpoint, functional selectivity introduces opportunities to tailor in-vitro phenotypes and to minimize signaling branches that confound interpretation in complex tissues. Future preclinical investigations can leverage this streamline—testing how sequence variants shift RXFP1 conformational ensembles, extending into phosphoproteomics to map downstream networks, and combining B7-33 with defined pathway modulators to resolve causal links between RXFP1 bias and tissue-level outcomes.
Conclusion
B7-33 exemplifies a rationally engineered, RXFP1-targeted peptidomimetic that emphasizes ERK-linked signaling while retaining context-dependent cAMP interplay. In preclinical models, this bias correlates with enhanced endothelial function in resistance vessels, reduced cardiomyocyte stress signaling, and favorable shifts in angiogenic factor balance in trophoblast systems. Collectively, these findings highlight RXFP1 as a versatile signaling hub and position B7-33 as a tractable probe for dissecting relaxin-pathway mechanisms across cardiovascular and placental biology. Continued work should define structure–bias relationships, quantify network-level effects across cell types, and standardize readouts to compare B7-33 with native relaxin-2 and other RXFP1 agonists in controlled laboratory environments.
References
- Marshall, S. A., O’Sullivan, K., Ng, H. H., Bathgate, R. A. D., Parry, L. J., Hossain, M. A., & Leo, C. H. (2017). B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin). European Journal of Pharmacology, 807, 190–197. https://doi.org/10.1016/j.ejphar.2017.05.005
- Mohammnad N. Uddin, Syeda H. Afroze, Ahmed F. Pantho, Nathan Drever, David C. Zawieja, Thomas J. Kuhel. (2017). 818: A single-chain derivative of the relaxin hormone (B7-33) protects cytotrophoblasts from hyperglycemia-induced preeclampsia phenotype and induces the survival pathway. American Journal of Obstetrics & Gynecology, 216(1, Suppl), S469–S470.
- Devarakonda, T., Mauro, A. G., Guzman, G., Hovsepian, S., Cain, C., Das, A., Praveen, P., Hossain, M. A., & Salloum, F. N. (2020). B7-33, a functionally selective relaxin receptor 1 agonist, attenuates myocardial infarction-related adverse cardiac remodeling in mice. Journal of the American Heart Association, 9(8), e015748. https://doi.org/10.1161/JAHA.119.015748
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
